After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Myriad Genetics, Inc. (MYGN) shows that investor sentiment remained same, with the stock’s consolidated last price to $17.87. The Myriad Genetics, Inc. has recorded 32,097 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers.
MYGN belongs to the Healthcare sector of the NASDAQ while operating in the Diagnostics & Research industry. At the end of the last regular session, the stock closed at $17.87 and fluctuated between $17.89 as its day high and $16.80 as its day low. The current market capitalization of Myriad Genetics, Inc. is $1.47B. A total of 0.87 million shares were traded on the day, compared to an average of 603.27K shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, MYGN has seen 2 BUY and 7 SELL insider trades, representing the acquisition of 20,000 and the disposition of 14,727 shares. Over the last 12 months, there were 20 BUYs and 47 SELLs from insiders. Insiders purchased 570,333 shares during that period but sold 280,415.
In the most recent transaction, Riggsbee Richard Bryan sold 30,000 shares of MYGN for 15.69 per share on Nov 01. After the transaction, the Chief Financial Officer now owns 321,812 company shares. In a previous transaction on Jun 02, SPIEGELMAN DANIEL K sold 8,638 shares at 23.01 per share. MYGN shares that Director owns now total 40,493.
Among the insiders who sold shares, Lambert Nicole disposed of 6,433 shares on Mar 27 at a per-share price of $23.48. This resulted in the Chief Operating Officer holding 240,506 shares of MYGN after the transaction. In another insider transaction, Riggsbee Richard Bryan sold 15,000 shares at $22.55 per share on Mar 02. Company shares held by the Chief Financial Officer now total 337,885.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for MYGN in the last 3 months, the mean price target is $20.38 with high estimates of $28.00 and low estimates of $12.00. In terms of 52-week highs and lows, MYGN has a high of $24.21 and a low of $13.82.
As of this writing, MYGN has an earnings estimate of $0.01 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of $0.02 per share and a lower estimate of $0.01.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. MYGN’s latest balance sheet shows that the firm has $339.80M in Cash & Short Term Investments as of fiscal 2021. There were $92.30M in debt and $204.30M in liabilities at the time. Its Book Value Per Share was $8.32, while its Total Shareholder’s Equity was $967.80M.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MYGN is Buy with a score of 3.00.